Stay updated with breaking news from Hans wildiers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The American Society for Clinical Oncology will use their annual meeting to ‘unequivocally recommit ourselves to patients’ whom they say are their ‘most ....
Milwaukee, WI (PRWEB) November 01, 2021 The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2021, ....
E-Mail BOSTON - A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors later years. The guidelines, published online today in a paper in JAMA Oncology, recommend discontinuing routine mammograms for survivors with a life expectancy under five years; considering stopping screening for those with a 5-10-year life expectancy; and continuing mammography for those whose life expectancy is greater than 10 years. The guidelines will be complemented by printed materials to help survivors gauge their risk of cancer recurring in the breast and weigh the potential benefits and drawbacks of mammography with their health care team. ....
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Shares of Immumetp Ltd. IMMP, , an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer. The company said overall survival data from a Phase 2b study evaluating its lead product candidate eftilagimod alpha in combination with chemotherapy performed well compared with placebo and chemotherapy. The overall trend in OS in total population was a median survival benefit of plus 2.7 months. However, in patients under 65 years of age, the benefit was 7.1 months. The data were presented at the San Antonio Breast Cancer Symposium which is taking place this week. Although the progression free survival data in the efti group did not show a significant improvement versus the comparator arm in AIPAC earlier this year, the OS data in general looks already very interesting and will mature further, AIPAC Principal Investigator, Hans Wildiers of University ....